Anti-obesity drugs consist of various pharmaceutical treatments aimed at helping individuals manage obesity and related health issues.

The global anti-obesity drugs market size is projected to grow from $12.8 billion in 2024 to $104.9 billion in 2035, representing a CAGR of 21.1%, till 2035. 

Anti-obesity drugs consist of various pharmaceutical treatments aimed at helping individuals manage obesity and related health issues. These medications provide healthcare professionals with valuable tools to complement lifestyle interventions, such as diet and exercise. They play a critical role in enhancing weight loss outcomes, particularly for patients with significant obesity-related comorbidities. Further, these drugs contribute to improved quality of life and potentially lower healthcare costs by preventing complications associated with obesity. Advancements in drug formulation and delivery systems, along with the integration of novel compounds, have led to the emergence of more effective and safer anti-obesity medications. The increasing focus on personalized medicine and pharmacogenomics further enhances the potential for tailored treatments that address individual patient needs. Additionally, the surge in telehealth services and digital therapeutics applications is facilitating better patient engagement and adherence to treatment regimens.

During our research, we identified 225 anti-obesity / weight loss drugs developed by close to 120 drug developers, worldwide. The anti-obesity drugs market is experiencing a steady growth, owing to the increasing prevalence of obesity and heightened awareness about the adverse effects associated with obesity.

A sizeable proportion (70%) of big pharma players have entered into partnerships to expand their current anti-obesity drug portfolio; followed by players (18%) undertaking various expansion initiatives. Over the years, various big pharmaceutical companies have marked their presence in the anti-obesity domain. These players have undertaken a number of initiatives in order to expand their respective drug portfolios and augment their capabilities. As can be observed in the figure, majority of the instances involved partnerships (70%), followed by expansion initiatives (18%). Recent example of partnership include agreement signed in September 2024 by Eli Lilly and Haya Therapeutics in order to utilize latter company’s proprietary technology for the identification and development of potential drug candidates for obesity and other metabolic disorders.

Research Methodology

Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Agricultural biologicals Market.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs. 

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Browse for more related reports

https://www.mountainproject.com/user/202070205/jhanvi-kukreja

https://www.upcarta.com/posts/243344

https://app.simplenote.com/p/DYrgGl

https://www.facetwig.com/read-blog/189998

https://community.shorthand.com/Feature-Wishlist/post/cold-chain-market-for-pharmaceuticals-share-global-industry-size-aWX6ZKaC7fXFl7n

https://www.musicaltouch.sg/profile/jhanvikukreja41638019/profile

https://www.ashevilleglamping.com/profile/jhanvikukreja41693542/profile

https://gitlab.chabokan.net/jhanvi0001/roots/-/issues/1

https://www.mountainproject.com/user/202070205/jhanvi-kukreja

https://oye.participer.lyon.fr/profiles/jhanvi001654/activity

http://inuyasha-fanfiction.com/viewuser.php?uid=61766

https://8x15m.mssg.me/

https://jali.pro/jhanvi933

https://www.upcarta.com/posts/243344

We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact:

Roots Analysis

[email protected]